- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Critical control point.
Displaying page 1 of 1.
EudraCT Number: 2005-003637-41 | Sponsor Protocol Number: BIOEU001.00 | Start Date*: 2005-10-26 |
Sponsor Name:Biopure Corporation | ||
Full Title: A Phase II, Multi-Center, Single-Blinded, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Hemoglobin-Based Oxygen Carrier-201 (HBOC-201, hemoglobin-glutamer-250 (bovine)]) on Wo... | ||
Medical condition: Wound Healing in Patients with Peripheral Vascular Disease and Who are Undergoing a Lower Limb Amputation due to Critical Lower Limb Ischemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000302-28 | Sponsor Protocol Number: EffICIENCY | Start Date*: 2020-05-04 |
Sponsor Name:Mundipharma Pharmaceuticals S.L. | ||
Full Title: Open randomized low interventional clinical trial to compare efficiency in symptom control between fluticasone propionate/formoterol k-haler at medium strength versus an high strength ICS/LABA for ... | ||
Medical condition: Persistent moderate asthma uncontrolled | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004117-27 | Sponsor Protocol Number: QUEPRO | Start Date*: 2018-02-27 |
Sponsor Name:IBSAL (Instituto de Investigación Biomédica de | ||
Full Title: CONTROLLED, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL FOR PROPHILAXIS OF POSOPERATIVE DELIRIUM IN HIGH RISK SURGICAL PATIENTS WITH QUETIAPINE. | ||
Medical condition: Postoperative delirium in high risk surgical patients. | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-001125-15 | Sponsor Protocol Number: ATB-202 | Start Date*: 2018-07-16 | |||||||||||||||||||||
Sponsor Name:Atox Bio | |||||||||||||||||||||||
Full Title: Phase III, randomized, double-blind, placebo controlled, parallel-group, study of AB103 as compared to placebo in patients with necrotizing soft tissue infections (NSTI) | |||||||||||||||||||||||
Medical condition: Necrosis of soft tissue infections (NSTI) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001162-12 | Sponsor Protocol Number: EFC16844 | Start Date*: 2020-03-26 | |||||||||||
Sponsor Name:Sanofi-aventis Recherche et Développement | |||||||||||||
Full Title: An adaptive phase 3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 | |||||||||||||
Medical condition: Corona virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002343-99 | Sponsor Protocol Number: 1.0 | Start Date*: 2012-01-03 |
Sponsor Name:Heart of England NHS Foundation Trust | ||
Full Title: An Open-label Study into the Efficacy and Dosing of Probiotic Escherichia coli Nissle 1917 for Prevention of Gram-negative Gastric Colonisation in Ventilated Intensive Care Patients. | ||
Medical condition: Gastric colonisation by pathogenic gram negative bacteria in ventilated adult ICU patients and it's prevention by the probiotic E.coli Nissle 1917 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004719-28 | Sponsor Protocol Number: D8850C00003 | Start Date*: 2020-11-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000875-33 | Sponsor Protocol Number: PLATA | Start Date*: 2013-08-27 | |||||||||||
Sponsor Name:Academic Medical Center, University of Amsterdam | |||||||||||||
Full Title: Prevention of Phantom Limb Pain After Transtibial Amputation (PLATA) - Randomized, double-blind, controlled, multi-center trial comparing Optimized intravenous pain control vs Optimized intravenous... | |||||||||||||
Medical condition: Phantom limb pain following amputation of the lower leg due to critical limb ischemia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) ES (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004356-16 | Sponsor Protocol Number: D8850C00002 | Start Date*: 2020-11-18 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000616-28 | Sponsor Protocol Number: AGMT_DISCOVER | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:AGMT gGmbH | |||||||||||||
Full Title: Multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of Dronabinol in the Improvement of ChemOthErapy-induced and tumor-Related... | |||||||||||||
Medical condition: Advanced pancreatic (locally advanced, inoperable or metastatic) cancer during first-line chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004108-16 | Sponsor Protocol Number: HOFATA_v3.0 | Start Date*: 2022-04-21 |
Sponsor Name:Medical University Vienna | ||
Full Title: Host factors predicting target site concentration of antibiotics in critically ill patients: An explorative pharmacokinetic biomarker study | ||
Medical condition: All patients given standard of care intravenous therapy of the studied antibiotics will be screened against the inclusion criteria. Two groups are included: Group A (septic patients with organ dysf... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000613-16 | Sponsor Protocol Number: CATCOVID-v1.2 | Start Date*: 2021-11-26 |
Sponsor Name:Charité – Universitätsmedizin Berlin | ||
Full Title: CCR1 antagonist treatment in patients hospitalized with COVID-19 A multi-centric, randomized, double-blind, and placebo-controlled clinical phase II trial | ||
Medical condition: Patients with acute SARS-CoV-2 infection, proven by a positive SARS-CoV-2 PCR test. The health status of the patients at inclusion in the clinical trial is rated 5 - 6 according to the WHO scale (s... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-004457-92 | Sponsor Protocol Number: PB2452-PT-CL-0004 | Start Date*: 2020-12-02 | |||||||||||
Sponsor Name:SFJ Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-Label, Single-Arm Study of PB2452 in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure ... | |||||||||||||
Medical condition: Uncontrolled Major or Life Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) AT (Completed) NL (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005535-24 | Sponsor Protocol Number: ABROGATE-5527 | Start Date*: 2016-06-07 | |||||||||||||||||||||
Sponsor Name:Univeristy of South Florida | |||||||||||||||||||||||
Full Title: Abatacept (CTLA4-Ig) for the treatment of relapsing, non-severe, granulomatosis with polyangiitis (Wegener's) | |||||||||||||||||||||||
Medical condition: Granulomatosis with polyangiitis (GPA; Wegener's granulomatosis) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003182-94 | Sponsor Protocol Number: BP40234 | Start Date*: 2018-02-27 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-... | ||||||||||||||||||
Medical condition: Advanced and/or Metastatic Solid Tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Completed) PL (Completed) DE (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002315-17 | Sponsor Protocol Number: MGL-3196-06 | Start Date*: 2017-01-12 | |||||||||||
Sponsor Name:Madrigal Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia | |||||||||||||
Medical condition: Heterozygous Familial Hypercholesterolemia (HeFH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005952-39 | Sponsor Protocol Number: COR-101/001 | Start Date*: 2021-03-12 | |||||||||||
Sponsor Name:CORAT Therapeutics GmbH | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, FIRST-IN-HUMAN, PHASE IB/II STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY, AN... | |||||||||||||
Medical condition: Treatment of symptomatic patients with moderate to severe coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002994-39 | Sponsor Protocol Number: Cx611-0204 | Start Date*: 2016-04-06 |
Sponsor Name:TIGENIX, S.A.U. | ||
Full Title: A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for... | ||
Medical condition: Severe community-acquired bacterial pneumonia requiring mechanical ventilation and/or vasopressors. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) BE (Completed) LT (Completed) GB (Completed) FR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-022914-15 | Sponsor Protocol Number: A3051123 | Start Date*: 2012-03-01 | |||||||||||
Sponsor Name:Pfizer, S.L.U. | |||||||||||||
Full Title: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYD... | |||||||||||||
Medical condition: Nicotine Addiction with the desire to quit smoking | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) DK (Completed) FI (Completed) BG (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004034-29 | Sponsor Protocol Number: A206T-G01-001 | Start Date*: 2018-12-19 | |||||||||||
Sponsor Name:Advanced Accelerator Applications International SA | |||||||||||||
Full Title: A Phase I/II open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients wi... | |||||||||||||
Medical condition: Patients with PSMA positive Metastatic Castration-resistant Prostate Cancer (mCRPC), and disease progression following previous systemic treatment for mCRPC. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
